IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, will participate in the 2025 BTIG Virtual Biotechnology Conference on July 29th, 2025. The company's President and CEO, Yujiro S. Hata, will engage in a fireside chat at 4:40 PM ET, hosted by BTIG's Director of Biotechnology Research Analysis, Justin Zelin.
The event will be accessible via live audio webcast through the company's investor relations website, with replay available for 30 days after the event.
IDEAYA Biosciences (NASDAQ: IDYA), un'azienda di oncologia di medicina di precisione, parteciper脿 alla Conferenza Virtuale di Biotecnologia BTIG 2025 il 29 luglio 2025. Il Presidente e CEO dell'azienda, Yujiro S. Hata, prender脿 parte a una conversazione informale alle 16:40 ET, condotta da Justin Zelin, Direttore dell'Analisi della Ricerca Biotecnologica di BTIG.
L'evento sar脿 accessibile tramite webcast audio in diretta sul sito web delle relazioni con gli investitori dell'azienda, con la possibilit脿 di rivederlo per 30 giorni dopo la trasmissione.
IDEAYA Biosciences (NASDAQ: IDYA), una compa帽铆a de oncolog铆a de medicina de precisi贸n, participar谩 en la Conferencia Virtual de Biotecnolog铆a BTIG 2025 el 29 de julio de 2025. El presidente y CEO de la compa帽铆a, Yujiro S. Hata, participar谩 en una charla informal a las 4:40 PM ET, presentada por Justin Zelin, Director de An谩lisis de Investigaci贸n en Biotecnolog铆a de BTIG.
El evento ser谩 accesible mediante una transmisi贸n de audio en vivo a trav茅s del sitio web de relaciones con inversionistas de la compa帽铆a, con repetici贸n disponible durante 30 d铆as despu茅s del evento.
IDEAYA 氚旍澊鞓れ偓鞚挫柛鞀� (NASDAQ: IDYA)電� 鞝曤皜 鞚橅暀 膦呾枒頃� 須岇偓搿滌劀 2025雲� 7鞗� 29鞚检棎 鞐措Μ電� 2025 BTIG 臧�靸� 靸濍獏瓿淀暀 旎嵓霟办姢鞐� 彀胳棳頃╇媹雼�. 須岇偓鞚� 靷灔 瓴� CEO鞚� 鞙犾搿� S. 頃橅儉電� BTIG 靸濍獏瓿淀暀 鞐瓣惮 攵勳劃 雼措嫻 鞚挫偓 鞝�鞀ろ嫶 鞝るΠ鞚� 歆勴枆頃橂姅 霃欕秬 響滌鞁� 鞓ろ泟 4鞁� 40攵�鞚� 雽�頇旍棎 彀胳棳頃� 鞓堨爼鞛呺媹雼�.
鞚� 頄夓偓電� 須岇偓鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞁れ嫓臧� 鞓る敂鞓� 鞗轨簮鞀ろ姼搿� 鞝滉车霅橂┌, 頄夓偓臧� 雭濍倻 頉� 30鞚� 霃欖晥 雼れ嫓氤搓赴臧� 臧�電ロ暕雼堧嫟.
IDEAYA Biosciences (NASDAQ : IDYA), une soci茅t茅 d'oncologie en m茅decine de pr茅cision, participera 脿 la Conf茅rence virtuelle de biotechnologie BTIG 2025 le 29 juillet 2025. Le pr茅sident et CEO de la soci茅t茅, Yujiro S. Hata, participera 脿 une discussion informelle 脿 16h40 ET, anim茅e par Justin Zelin, directeur de l'analyse de la recherche en biotechnologie chez BTIG.
L'茅v茅nement sera accessible via un webcast audio en direct sur le site des relations investisseurs de la soci茅t茅, avec une rediffusion disponible pendant 30 jours apr猫s l'茅v茅nement.
IDEAYA Biosciences (NASDAQ: IDYA), ein Unternehmen f眉r Pr盲zisionsmedizin in der Onkologie, wird am BTIG Virtual Biotechnology Conference 2025 am 29. Juli 2025 teilnehmen. Der Pr盲sident und CEO des Unternehmens, Yujiro S. Hata, wird um 16:40 Uhr ET an einem Gespr盲ch am Kamin teilnehmen, moderiert von Justin Zelin, Direktor der Biotechnologieforschungsanalyse bei BTIG.
Die Veranstaltung ist 眉ber einen Live-Audio-Webcast auf der Investor-Relations-Website des Unternehmens zug盲nglich, mit einer Wiedergabeoption f眉r 30 Tage nach der Veranstaltung.
- None.
- None.
2025 BTIG Virtual Biotechnology Conference
Tuesday, July 29th, 2025 at 4:40 PM ET
- Fireside chat with聽Yujiro S. Hata, President and Chief Executive Officer, hosted by聽Justin Zelin, Director, Biotechnology Research Analyst
A live audio webcast of the conference event, as permitted by the conference host, will be available at the "Investors/Events" section of the IDEAYA website at and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
[email protected]
View original content to download multimedia:
SOURCE IDEAYA Biosciences, Inc.
FAQ
When is IDEAYA Biosciences (IDYA) presenting at the BTIG Virtual Biotechnology Conference 2025?
Who will be presenting at the IDEAYA Biosciences (IDYA) BTIG conference?
How can investors access IDEAYA Biosciences' (IDYA) BTIG conference presentation?
What type of company is IDEAYA Biosciences (IDYA)?
